DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

Phase 4 Completed 14 enrolled Kirby Institute Janssen-Cilag Ltd. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin, Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.

Timeline

Start: 2013-01
Primary completion: 2015-11
Completion: 2016-01

Publications

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Antivir Ther. 2016;21(5):425-34. doi: 10.3851/IMP3035. Epub 2016 Feb 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	Subcutaneous
Subject	Ribavirin	Small molecule	1000 mg	Oral
Subject	Ribavirin	Small molecule	1200 mg	Oral
Subject	Telaprevir	Small molecule	1125 mg	Oral

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

Summary

Timeline

Publications

Drugs

Indications